Study to determine rate of absorption or bioavailability of amphetamine extended-release liquid formulation (AMP XR-OS) in patient with attention-deficit/hyperactivity disorder.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Jan 2018

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

10 Jan 2018 According to a Neos Therapeutics media release, results from this trial will be presented at the 2018 Annual Meeting of the American Professional Society of ADHD and Related Disorders (APSARD).
30 Nov 2017 New trial record
22 Nov 2017 Results assessing bioavailability of amphetamine after administration of AMP XR-OS to healthy adult volunteers, were published in the Clinical Therapeutics.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com